Breakthrough Products Should Be Free Of PDUFA Constraints, Sponsors Say
Executive Summary
The types of FDA/sponsor interactions and timelines for meetings should not be limited by the user fee measure, industry commenters say in response to FDA’s draft guidance on expedited pathways. Some patient advocacy groups urge FDA to reconsider plans for withdrawing breakthrough designation in certain situations.
You may also be interested in...
Emerging Sponsors And FDA: Will Better Communication Under PDUFA V Ease Inherent Tensions?
New communication mechanisms built into the Prescription Drug User Fee Act V agreement are unlikely to be the panacea for the regulatory, economic and public relations challenges created when a small company attempts to bring its first drug to market.
Drug Shortages, Inspections In Focus At US FDA Appropriations Hearing
Commissioner Robert Califf discussed the agency’s request for $12.3m to address shortages and legislation to require that manufacturers provide more detailed information about increased demand and supply chain vulnerabilities.
Clinical Trial Diversity Requires Sponsors Work With An Assortment Of Patient Advocates, Community Organizations
US FDA oncology officials are concerned that the entities sponsors are consulting in developing and implementing clinical trial diversity plans are not sufficiently diverse themselves and do not represent patients in underserved communities.